I'm LongbridgeAI, I can summarize articles.Avricore Health's subsidiary, HealthTab, signed a multi-year agreement with Abbott to supply and distribute point-of-care testing products in UK community pharmacies. The deal focuses on deploying the Afinion 2 analyzer for HbA1c and lipid profile testing within NHS-linked pharmacies, supported by HealthTab's cloud platform for data integration. Meanwhile, TipRanks' AI analyst rates AVCR stock as Neutral due to deteriorating financial performance, despite a low-debt balance sheet.
Avricore Health ( (TSE:AVCR) ) has shared an announcement.
On August 20, 2026, Avricore’s HealthTab subsidiary signed a multi-year collaboration agreement with global healthcare group Abbott to supply and distribute Abbott’s point-of-care testing products across UK community pharmacies. The deal initially centres on deploying the Afinion 2 analyzer in NHS-linked pharmacies for HbA1c and lipid profile testing, anchoring a structured framework for broader pharmacy-based point-of-care expansion in the country.
HealthTab’s secure cloud platform connects analyzers, patient results, quality-control data and pharmacist workflows to create a unified, scalable digital infrastructure for community testing. Supported by a rigorous quality management program run with CEQAL Inc., the network is designed to deliver lab-grade accuracy and real-time analytics, strengthening Avricore’s positioning in pharmacy-based diagnostics and potentially improving public-health reporting and patient care outcomes.
Spark’s Take on AVCR Stock
According to Spark, TipRanks’ AI Analyst, AVCR is a Neutral.
The score is held down primarily by deteriorating financial performance (very low TTM revenue, negative gross profit, widening losses, and negative operating/free cash flow), only partly offset by a low-debt balance sheet. Technical indicators are neutral-to-mildly positive, but valuation is hard to support with a negative P/E and no dividend data.
To see Spark’s full report on AVCR stock,
click here.
More about Avricore Health
Avricore Health Inc. is a Canadian pharmacy service innovator focused on acquiring and developing early-stage technologies that enhance pharmacy practice and patient care. Through its wholly owned subsidiary HealthTab™, the company aims to build the world’s largest network of rapid point-of-care testing devices in community pharmacies, making actionable health information more accessible to patients and healthcare providers.
Average Trading Volume: 53,143
Technical Sentiment Signal: Sell
Current Market Cap: C$7.58M